36 / 52
86
VOLUME 13 NUMBER 2 • DECEMBER 2016
REVIEW
SA JOURNAL OF DIABETES & VASCULAR DISEASE
45. Gilardini L, McTernan PG, Girola A, da Silva NF, Alberti L, Kumar S,
et al
.
Adiponectin is a candidate marker of metabolic syndrome in obese children and
adolescents.
Atherosclerosis
2006;
189
: 401–407.
46. Mohan V, Deepa R, Pradeepa R, Vimaleswaran KS, Mohan A, Velmurugan K,
et al
.
Association of low adiponectin levels with the metabolic syndrome – the Chennai
Urban Rural Epidemiology Study (CURES-4).
Metabolism
2005;
54
: 476–481.
47. Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y,
et al
. Novel
modulator for endothelial adhesion molecules: adipocyte-derived plasma protein
adiponectin.
Circulation
1999;
100
: 2473–2476.
48. Wang ZV, Scherer PE. Adiponectin, cardiovascular function, and hypertension.
Hypertension
2008;
51
: 8–14.
49. Fruebis J, Tsao TS, Javorschi S, Ebbets-Reed D, Erickson MR, Yen FT,
et al
.
Proteolytic cleavage product of 30-kDa adipocyte complement-related protein
increases fatty acid oxidation in muscle and causes weight loss in mice.
Proc Natl
Acad Sci USA
2001;
98
: 2005–2010.
50. Berg AH, Combs TP, Du X, Brownlee M, Scherer PE. The adipocyte-secreted
protein Acrp30 enhances hepatic insulin action.
Nat Med
2001;
7
: 947–953.
51. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K,
et al
. The fat-derived
hormone adiponectin reverses insulin resistance associated with both lipoatrophy
and obesity.
Nat Med
2001;
7
: 941–946.
52. Okamoto M, Ohara-Imaizumi M, Kubota N, Hashimoto S, Eto K, Kanno T,
et al
. Adiponectin induces insulin secretion in vitro and in vivo at a low glucose
concentration.
Diabetologia
2008;
51
: 827–835.
53. Kubota N, Yano W, Kubota T, Yamauchi T, Itoh S, Kumagai H,
et al
. Adiponectin
stimulates AMP-activated protein kinase in the hypothalamus and increases food
intake.
Cell Metab
2007;
6
: 55–68.
54. Beauloye V, Zech F, Tran HT, Clapuyt P, Maes M, Brichard SM. Determinants of
early atherosclerosis in obese children and adolescents.
J Clin Endocrinol Metab
2007;
92
: 3025–3032.
55. Kato H, Kashiwagi H, Shiraga M, Tadokoro S, Kamae T, Ujiie H,
et al
. Adiponectin
acts as an endogenous antithrombotic factor.
Arterioscler Thromb Vasc Biol
2006;
26
: 224–230.
56. Heinonen MV, Purhonen AK, Miettinen P, Paakkonen M, Pirinen E, Alhava E,
et al
.
Apelin, orexin-A and leptin plasma levels in morbid obesity and effect of gastric
banding.
Regul Pept
2005;
130
: 7–13.
57. Dray C, Knauf C, Daviaud D, Waget A, Boucher J, Buleon M,
et al
. Apelin
stimulates glucose utilization in normal and obese insulinresistant mice.
Cell
Metab
2008;
8
: 437–445.
58. Kuba K, Zhang L, Imai Y, Arab S, Chen M, Maekawa Y,
et al
. Impaired heart
contractility in Apelin gene-deficient mice associated with aging and pressure
overload.
Circ Res
2007;
101
: e32–e42.
59. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K,
et
al
. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin.
Science
2005;
307
: 426–430.
60. Berndt J, Kloting N, Kralisch S, Kovacs P, Fasshauer M, Schon MR,
et al
. Plasma
visfatin concentrations and fat depot-specific mRNA expression in humans.
Diabetes
2005;
54
: 2911–2916.
61. Varma V, Yao-Borengasser A, Rasouli N, Bodles AM, Phanavanh B, Lee MJ,
et
al
. Human visfatin expression: relationship to insulin sensitivity, intramyocellular
lipids, and inflammation.
J Clin Endocrinol Metab
2007;
92
: 666–672.
62. Garten A, Petzold S, Korner A, Imai S, Kiess W. Nampt: linking NAD biology,
metabolism and cancer.
Trends Endocrinol Metab
2009;
20
: 130–138.
63. Hida K, Wada J, Eguchi J, Zhang H, Baba M, Seida A,
et al
. Visceral adipose
tissue-derived serine protease inhibitor: a unique insulinsensitizing adipocytokine
in obesity.
Proc Natl Acad Sci USA
2005;
102
: 10610–10615.
64. Youn BS, Kloting N, Kratzsch J, Lee N, Park JW, Song ES,
et al
. Serum vaspin
concentrations in human obesity and type 2 diabetes.
Diabetes
2008;
57
: 372–
377.
65. Bozaoglu K, Bolton K, McMillan J, Zimmet P, Jowett J, Collier G,
et al
. Chemerin is
a novel adipokine associated with obesity and metabolic syndrome.
Endocrinology
2007;
148
: 4687–4694.
66. Goralski KB, McCarthy TC, Hanniman EA, Zabel BA, Butcher EC, Parlee SD,
et al
. Chemerin, a novel adipokine that regulates adipogenesis and adipocyte
metabolism.
J Biol Chem
2007;
282
: 28175–28188.
67. Takahashi M, Takahashi Y, Takahashi K, Zolotaryov FN, Hong KS, Kitazawa R,
et al
.
Chemerin enhances insulin signaling and potentiates insulin-stimulated glucose
uptake in 3T3-L1 adipocytes.
FEBS Lett
2008;
582
: 573–578.
68. Roh SG, Song SH, Choi KC, Katoh K, Wittamer V, Parmentier M,
et al
. Chemerin
– a new adipokine that modulates adipogenesis via its own receptor.
Biochem
Biophys Res Commun
2007;
362
: 1013–1018.
69. Ernst MC, Issa M, Goralski KB, Sinal CJ. Chemerin exacerbates glucose intolerance
in mouse models of obesity and diabetes.
Endocrinology
2010;
151
: 1998–
2007.
70. Sell H, Laurencikiene J, Taube A, Eckardt K, Cramer A, Horrighs A,
et al
.
Chemerin is a novel adipocyte-derived factor inducing insulin resistance in
primary human skeletal muscle cells.
Diabetes
2009;
58
: 2731–2740.
71. Akinboboye O, Idris O, Akinboboye O, Akinkugbe O. Trends in coronary artery
disease and associated risk factors in sub-Saharan Africans.
J Hum Hypertens
2003;
17
: 381–387.
72. Tibazarwa K, Ntyintyane L, Sliwa K, Gerntholtz T, Carrington M, Wilkinson D,
et al
.
A time bomb of cardiovascular risk factors in South Africa: results from the Heart of
Soweto Study ‘Heart Awareness Days’.
Int J Cardiol
2009;
132
: 233–239.
73. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases:
part I: general considerations, the epidemiologic transition, risk factors, and impact
of urbanization.
Circulation
2001;
104
: 2746–2753.
74. Walker AR, Sareli P. Coronary heart disease: outlook for Africa.
J R Soc Med
1997;
90
: 23–27.
75. Ferris WF, Naran NH, Crowther NJ, Rheeder P, van der ML, Chetty N. The
relationship between insulin sensitivity and serum adiponectin levels in three
population groups.
Horm Metab Res
2005;
37
: 695–701.
76. Mbanya JC, Motala AA, Sobngwi E, Assah FK, Enoru ST. Diabetes in sub-
Saharan Africa.
Lancet
2010;
375
: 2254–2266.
77. Ali AT, Crowther NJ. Body fat distribution and insulin resistance.
S Afr Med J
2005;
95
: 878–880.
78. Van der Merwe M-T, Crowther NJ, Schlaphoff GP, Gray IP, Joffe BI, Lönnroth
PN. Evidence for insulin resistance in black women from South Africa.
Int J
Obes
2000;
24
: 1340–1346.
79. Goedecke JH, Levitt NS, Lambert EV, Utzschneider KM, Faulenbach MV, Dave
JA,
et al
. Differential effects of abdominal adipose tissue distribution on
insulin sensitivity in black and white South African women.
Obesity
2009;
17
:
1506–1512.
80. Crowther NJ, Ferris WF, Ojwang PJ, Rheeder P. The effect of abdominal obesity
on insulin sensitivity and serum lipid and cytokine concentrations in African
women.
Clin Endocrinol
(Oxf) 2006;
64
: 535–541.
81. Walker AR, Walker BF, Manetsi B, Tsotetsi NG, Walker AJ. Obesity in
black women in Soweto, South Africa: minimal effects on hypertension,
hyperlipidaemia and hyperglycaemia.
J R Soc Hlth
1990;
110
: 101–103.
82. Ali AT, Crowther NJ. The relationship between national socio-economic
variables and obesity prevalence rates in Africa and Europe.
J Endocrinol
Metab Diabetes S Afr
2010;
15
: 29.
83. Eckel RH. Insulin resistance: an adaptation for weight maintenance.
Lancet
1992;
340
: 1452–1453.
84. Swinburn BA, Nyomba BL, Saad MF, Zurlo F, Raz I, Knowler WC,
et al
. Insulin
resistance associated with lower rates of weight gain in Pima Indians.
J Clin
Invest
1991;
88
: 168–173.
85. Frayn KN, Humphreys SM, Coppack SW. Net carbon flux across subcutaneous
adipose tissue after a standard meal in normal-weight and insulin-resistant
obese subjects.
Int J Obes Relat Metab Disord
1996;
20
: 795–800.
86. Pond CM. Adipose tissue and the immune system.
Prostaglandins Leukot
Essent Fatty Acids
2005;
73
: 17–30.
87. Farooqi IS, Matarese G, Lord GM, Keogh JM, Lawrence E, Agwu C,
et al
.
Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and
neuroendocrine/metabolic dysfunction of human congenital leptin deficiency.
J Clin Invest
2002;
110
: 1093–1103.
88. Young C, Jarrell BE, Hoying JB, Williams SK. A porcine model for adipose
tissue-derived endothelial cell transplantation.
Cell Transpl
1992;
1
: 293–298.
89. Tholpady SS, Llull R, Ogle RC, Rubin JP, Futrell JW, Katz AJ. Adipose tissue:
stem cells and beyond.
Clin Plast Surg
2006;
33
: 55–62.
90. Zuk PA, Zhu M, Ashjian P, De Ugarte DA, Huang JI, Mizuno H,
et al
. Human adipose
tissue is a source of multipotent stem cells.
Mol Biol Cell
2002;
13
: 4279–4295.
91. Wickham MQ, Erickson GR, Gimble JM, Vail TP, Guilak F. Multipotent stromal
cells derived from the infrapatellar fat pad of the knee.
Clin Orthop Relat Res
2003;
412
: 196–212.
92. Gimble J, Guilak F. Adipose-derived adult stem cells: isolation, characterization,
and differentiation potential.
Cytotherapy
2003;
5
: 362–369.
93. Zuk PA, Zhu M, Mizuno H, Huang J, Futrell JW, Katz AJ,
et al
. Multi-lineage
cells from human adipose tissue: implications for cell-based therapies.
Tissue
Eng
2001;
7
: 211–228.
94. Gronthos S, Franklin DM, Leddy HA, Robey PG, Storms RW, Gimble JM.
Surface protein characterization of human adipose tissue-derived stromal
cells.
J Cell Physiol
2001;
189
: 54–63.
95. Gimble JM, Guilak F. Differentiation potential of adipose derived adult stem
(ADAS) cells.
Curr Top Dev Biol
2003;
58
: 137–160.
96. Rangappa S, Fen C, Lee EH, Bongso A, Sim EK. Transformation of adult
mesenchymal stem cells isolated from the fatty tissue into cardiomyocytes.
Ann
Thorac Surg
2003;
75
: 775–779.